US2024043428A1PendingUtilityA1

Pyrrolopyrimidine compounds and their uses

82
Assignee: NOVARTIS AGPriority: Aug 22, 2008Filed: Dec 21, 2022Published: Feb 8, 2024
Est. expiryAug 22, 2028(~2.1 yrs left)· nominal 20-yr term from priority
C07D 487/04A61P 35/00C07D 487/08A61K 31/519C07D 519/00A61P 25/28A61P 29/00A61P 35/02A61P 35/04A61P 37/00A61P 37/06A61P 43/00
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.

Claims

exact text as granted — not AI-modified
1 - 22 . (canceled) 
     
     
         23 . A compound 7-Cyclopentyl-2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridazin-3-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide of the formula 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.